Dupixent severe asthma results should propel Sanofi, Regeneron drug to billions more in sales

11th September 2017 Uncategorised 0

Dupixent, the Sanofi and Regeneron drug already on a blockbuster arc in atopic dermatitis, has returned significant results in patients with severe asthma, another indication that is expected to add billions of dollars more in sales for the partners.

More: Dupixent severe asthma results should propel Sanofi, Regeneron drug to billions more in sales
Source: fierce